Dementia with Lewy Bodies (DLB) Characteristics and Management

Pathophysiology and Clinical Features

The constellation of visual hallucinations, parkinsonism, dementia, and autonomic dysfunction is caused by Dementia with Lewy Bodies (DLB), a neurodegenerative disorder characterized by abnormal deposits of alpha-synuclein protein (Lewy bodies) throughout the cortex, subcortical regions, and autonomic nervous system 1, 2
DLB results from misfolded alpha-synuclein protein accumulation that initially deposits in the medulla oblongata, pontine tegmentum, and olfactory system, then progresses to involve the substantia nigra and deep gray nuclei, and finally spreads to the cortex 2

Recurrent, well-formed, detailed visual hallucinations typically involving people, animals, or objects are a core clinical feature of DLB 2, 3
The American Academy of Neurology recommends considering DLB in patients with dementia and parkinsonism, where cognitive symptoms coincide with or precede parkinsonism within 1 year 1
The disease represents a distinct clinical entity, different from Parkinson's Disease Dementia (PDD) and Alzheimer's disease with behavioral disturbances, characterized by visual hallucinations, fluctuating cognition, and REM sleep behavior disorder (RBD) 2

Cholinesterase inhibitors are the first-line treatment for DLB, addressing both cognitive symptoms and visual hallucinations, and should be continued even if cognitive decline progresses, as long as they provide meaningful reduction in hallucinations 3
Traditional antipsychotics must be avoided due to severe neuroleptic sensitivity reactions that significantly increase morbidity and mortality in DLB patients 2
Patient and caregiver education about hallucinations significantly reduces anxiety and fear, and simple coping strategies, such as eye movements, changing lighting, or distraction techniques, can effectively manage hallucinations 3